Study Assesses Risk of Secondary AML in Patients With Myeloproliferative Neoplasms

Study Assesses Risk of Secondary AML in Patients With Myeloproliferative Neoplasms
Study Assesses Risk of Secondary AML in Patients With Myeloproliferative Neoplasms

Among patients with myeloproliferative neoplasms, men with primary myelofibrosis diagnosed after 2006 are at the highest risk of developing secondary acute myeloid leukemia (AML), according to a study published in conjunction with the 2016 annual meeting of the American Society of Clinical Oncology (ASCO).1

For the study, researchers analyzed data from 9335 patients with polycythemia vera (43.8%), primary myelofibrosis (11.8%), and essential thrombocythemia (44.4%) diagnosed between 2000 and 2012 and included in the Surveillance, Epidemiology, and End Results (SEER) database to determine the risk of secondary AML in this patient population.

With a median follow-up of 48 months, results showed that 83 patients developed secondary AML. Median age at diagnosis of AML was 72 years, 69% were male, and 80% were white.

Researchers found that the cumulative incidence of secondary AML was 0.74% (95% CI, 0.56-0.97) and 1.62% (95% CI, 1.24-2.09) at 5 and 10 years, respectively. The 10-year cumulative incidence was higher in patients with primary myelofibrosis (2.96%; 95% CI, 1.90-4.39) compared with those with essential thrombocythemia (1.68%; 95% CI, 1.03-2.62) and polycythemia vera (1.24%; 95% CI, 0.81-1.83) (P <.001).

The study further demonstrated that the 10-year cumulative incidence was higher in males than females (P <.001) and in patients older than 60 years vs those 60 years or younger (P =.04).

These findings may be used to enhance education of patients with myeloproliferative disorders at risk for developing a secondary hematologic malignancy.

Reference

1. Paluri S, Giri S, Shrestha R, et al. Secondary acute myeloid leukemia (sAML) in patients with myeloproliferative disorder (MPD). J Clin Oncol. 2016;34(suppl):Abstr e18513.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs